GLTO

Company Overview — What Does Galecto, Inc. Do?

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto, Inc. (GLTO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Hans T. Schambye and employs approximately 40 people. With a market capitalization of $1.7B, GLTO is one of the notable companies in the Healthcare sector.

Galecto, Inc. (GLTO) Stock Rating — Hold (April 2026)

As of April 2026, Galecto, Inc. receives a Hold rating with a composite score of 37.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.GLTO ranks #1,238 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Galecto, Inc. ranks #93 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GLTO Stock Price and 52-Week Range

Galecto, Inc. (GLTO) currently trades at $28.91. The stock gained $0.55 (1.9%) in the most recent trading session. The 52-week high for GLTO is $38.33, which means the stock is currently trading -24.6% from its annual peak. The 52-week low is $2.01, putting the stock 1338.3% above its annual trough. Recent trading volume was 133K shares, suggesting relatively thin trading activity.

Is GLTO Overvalued or Undervalued? — Valuation Analysis

Galecto, Inc. (GLTO) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 7.26x, compared to the Healthcare sector average of 23.63x — a discount of 69%. The price-to-book ratio stands at 7.19x, versus the sector average of 2.75x. The price-to-sales ratio is 10411.37x, compared to 1.66x for the average Healthcare stock.

At current multiples, Galecto, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Galecto, Inc. Profitability — ROE, Margins, and Quality Score

Galecto, Inc. (GLTO) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -5.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -5.0% versus the sector average of -33.1%.

The operating margin is -5956.2% (sector: -66.1%). Net profit margin stands at -5868.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -80.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GLTO Debt, Balance Sheet, and Financial Health

Galecto, Inc. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.98x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $8M.

GLTO has a beta of 1.79, meaning it is more volatile than the broader market — a $10,000 investment in GLTO would be expected to move 78.9% more than the S&P 500 on any given day. The stability factor score for Galecto, Inc. is 9/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Galecto, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Galecto, Inc. reported revenue of $166,000 and earnings per share (EPS) of $3.98. Net income for the quarter was $-13M. Gross margin was 0.0%. Operating income came in at $-13M.

In FY 2025, Galecto, Inc. reported revenue of $1M and earnings per share (EPS) of $3.98. Net income for the quarter was $-210M. Revenue grew 38.3% year-over-year compared to FY 2024. Operating income came in at $-211M.

In Q3 2025, Galecto, Inc. reported revenue of $42,000 and earnings per share (EPS) of $-2.36. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, Galecto, Inc. reported revenue of $50,000 and earnings per share (EPS) of $-2.60. Net income for the quarter was $-3M. Revenue grew -76.5% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Galecto, Inc. has experienced revenue contraction from $213,000 to $166,000. Investors analyzing GLTO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GLTO Dividend Yield and Income Analysis

Galecto, Inc. (GLTO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GLTO Momentum and Technical Analysis Profile

Galecto, Inc. (GLTO) has a momentum factor score of 76/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.

GLTO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Galecto, Inc. (GLTO) ranks #93 out of 838 stocks based on the Blank Capital composite score. This places GLTO in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GLTO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GLTO vs S&P 500 (SPY) comparison to assess how Galecto, Inc. stacks up against the broader market across all factor dimensions.

GLTO Next Earnings Date

No upcoming earnings date has been announced for Galecto, Inc. (GLTO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GLTO? — Investment Thesis Summary

Galecto, Inc. presents a balanced picture with arguments on both sides. The quality score of 19/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 76/100, suggesting the trend favors buyers. High volatility (stability score 9/100) increases portfolio risk.

In summary, Galecto, Inc. (GLTO) earns a Hold rating with a composite score of 37.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GLTO stock.

Related Resources for GLTO Investors

Explore more research and tools: GLTO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GLTO head-to-head with peers: GLTO vs AZN, GLTO vs SLGL, GLTO vs VMD.